Tech Partnership Tackles America's Hidden Sleep Apnea Epidemic

LOS ANGELES, CA – September 01, 2026 – An estimated 83 million Americans suffer from sleep apnea, yet a staggering 80% of them navigate their lives completely unaware they have the condition. This isn't a failure of individual awareness but a systemic breakdown—a healthcare pathway so fragmented and cumbersome that millions who suffer from chronic fatigue, high blood pressure, and increased risk of heart failure never receive a proper diagnosis. Now, a new partnership aims to pave over that broken path with digital efficiency, potentially revolutionizing access to care for one of the nation's most pervasive and underdiagnosed chronic conditions.

Daybreak, a solutions company offering a fully at-home model for sleep apnea diagnosis and treatment, has officially joined Parachute Health, the country's largest ePrescribing platform for home medical equipment (HME). The integration places Daybreak's innovative service directly into the digital workflow of over 300,000 clinicians, creating a streamlined, one-click referral process that aims to replace an archaic system of faxes, phone calls, and frustrating administrative delays.

A System Long Overdue for an Overhaul

The journey from suspecting sleep apnea to receiving effective treatment has historically been a logistical nightmare. It often begins with a primary care physician, proceeds to a specialist referral with long wait times, and culminates in an inconvenient and expensive overnight stay at a sleep lab for a polysomnogram. For those who complete this gauntlet and receive a diagnosis, another set of hurdles emerges involving equipment suppliers and insurance verification. Each step is a potential point of failure where patients can drop out of the process.

"Obstructive sleep apnea remains widely underdiagnosed and undertreated in the United States, in part because the path from testing to treatment has historically been fragmented across multiple systems and providers," said Wesley Lones, Founder and CEO of Daybreak. This fragmentation is the primary culprit behind the massive diagnosis gap. Research confirms that poor care coordination, coupled with patient reluctance to undergo inconvenient in-lab studies, are significant barriers. For the millions in underserved communities with limited access to specialist clinics, the pathway is often a dead end.

The consequences of this systemic failure are severe. Untreated obstructive sleep apnea (OSA) is linked to a host of serious health problems, including hypertension, heart disease, stroke, and Type 2 diabetes. The constant sleep interruptions prevent restorative rest, leading to debilitating daytime fatigue that impacts work performance, mental health, and public safety.

The Digital Prescription: Connecting Patients to At-Home Care

The Daybreak and Parachute Health collaboration attacks this problem at its source: the administrative friction between prescribers, patients, and equipment providers. Parachute Health has established itself as the digital infrastructure for the HME industry, transforming a paper-based ordering system into a modern, connected platform. By embedding Daybreak within this ecosystem, the partnership makes ordering a comprehensive sleep apnea solution as simple as prescribing any other piece of medical equipment.

"Physicians already place HME orders through Parachute’s platform as part of their normal workflow, so a sleep apnea referral to Daybreak now works the same way,” explained Eric Mongeau, Chief Commercial Officer of Daybreak. “ePrescribing through Parachute Health turns what used to be a multi-day back-and-forth into a streamlined digital process.”

For a busy clinician, this is a game-changer. Instead of navigating a complex, multi-step referral, they can now order Daybreak’s end-to-end service directly from the patient's electronic health record. This single action triggers the entire care pathway, from shipping an at-home test to coordinating treatment. The integration provides the digital rails that connect the disparate parts of the care journey, significantly reducing the administrative burden that has long plagued providers and delayed patient care.

“Parachute strives to decrease the friction between prescribers, HME providers, and patients through our digital workflows," noted Rob Boeye, EVP, Commercial Leader for HME at Parachute Health. By making Daybreak available on the platform, the company extends its mission of efficiency into the complex world of sleep medicine, offering a tangible solution to a long-standing access problem.

Reimagining Treatment: The Rise of At-Home Solutions

Simplifying the referral is only half the battle; the solution itself must be accessible and effective. This is where Daybreak's patient-centric model comes into play. The company has dismantled the traditional, clinic-bound process and rebuilt it entirely around the patient's home.

Once a referral is made, Daybreak sends the patient an FDA-cleared at-home sleep test (HST). These modern diagnostic tools are a far cry from the intimidating, wire-laden in-lab studies of the past. Clinical studies have shown that for patients with typical symptoms, HSTs can accurately identify obstructive sleep apnea more than 90% of the time, making them a reliable and convenient first step for diagnosis.

Following a diagnosis—either from the patient's own physician or via Daybreak's telehealth consultation—the focus shifts to treatment. While CPAP machines are the most well-known therapy, their bulky masks and forced air pressure lead to notoriously low compliance rates, with some estimates suggesting over 50% of users abandon the therapy. Daybreak offers a powerful alternative: a custom-fit, FDA-cleared mandibular advancement device (MAD). This oral appliance, which resembles a mouthguard, works by gently moving the lower jaw forward during sleep, which is enough to open the airway and relieve snoring and apnea.

For mild-to-moderate OSA, the American Academy of Sleep Medicine endorses oral appliance therapy as a first-line treatment. Crucially, due to its comfort and ease of use, patient adherence to MADs is significantly higher than with CPAP. This real-world compliance often makes it a more clinically effective solution over the long term. A recent study associated with Cedars Sinai demonstrated that Daybreak's telehealth-guided pathway for its oral appliance produced clinical outcomes comparable to, or even better than, traditional in-clinic studies, validating the efficacy of its virtual care model.

Navigating the Real-World Hurdles of Healthcare Innovation

While promising, the success of this digital partnership hinges on clearing real-world hurdles, primarily insurance coverage and physician adoption. Fortunately, the groundwork is already laid. Most major insurance plans, including Medicare, now cover medically necessary at-home sleep tests. Oral appliances are also typically covered for OSA, particularly when CPAP is not tolerated. By working directly with insurers, Daybreak aims to minimize out-of-pocket costs for patients, removing a critical financial barrier.

The ultimate test will be adoption. With access to the 70,000 facilities and health systems on the Parachute Health platform, Daybreak has an unprecedented opportunity to scale its model. The key will be educating clinicians not only on the ease of the new digital workflow but also on the clinical validity and patient benefits of an at-home care pathway and oral appliance therapy.

This partnership represents more than just a new service offering; it is a powerful case study in leveraging existing digital infrastructure to solve a deeply entrenched healthcare access problem. By connecting an innovative, patient-friendly solution to the e-prescribing tools that physicians already trust, it creates a pathway of least resistance. For the tens of millions of Americans living with the silent burden of undiagnosed sleep apnea, the path from silent suffering to restful sleep may have just become significantly shorter.